A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Ewing's sarcoma; Hepatoblastoma; Langerhans cell histiocytosis; Medulloblastoma; Neuroblastoma; Retinoblastoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- 05 Oct 2021 Status changed from recruiting to discontinued.
- 21 Sep 2020 Results (n=82) presented at the 45th European Society for Medical Oncology Congress
- 04 Jun 2019 Results (n=30) assessing efficacy and safety of the combination of nivolumab and ipilimumab in adult patients published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)